Branded formulations drive Eris Lifesciences' Q2 PAT up by 10% to Rs 118 cr
Revenue from operations grow 9% YoY to Rs 360 crore29-10-2021
29-10-2021
Q2FY22 Quarterly Result Announced for Eris Lifesciences Ltd.
FINANCIAL HIGHLIGHTS Favourable product mix resulting in 192 bps increase in standalone gross margin and 294 bps in standalone EBITDA margin (42.5%) in Q2 FY22 Standalone debtor days = 39 at the end of Q2 FY22 Consol. Net Profit Margin at 32.9% in Q2 FY22 Standalone YPM grew from INR 4.60 lacs in H1 FY21 to INR 5.13 lacs in H1 FY22; a yoy growth of 11% Consol. other expenses grew 14.7% yoy in H1 FY22 led by a gradual normalisation of field activities Consol. Net Profit margin stable at 31.7% yoy for H1 FY22 Result PDF29-10-2021
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation
INVESTOR PRESENTATION29-10-2021
Eris Lifesciences Ltd - 540596 - Results-Financial Results For September 30, 2021
The Board of Directors of the Company at their meeting held today i.e. October 29, 2021 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2021.29-10-2021
Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING HELD TODAY, I.E. OCTOBER 29, 2021
The Board of Directors of the Company at their meeting held today i.e. October 29, 2021 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2021.29-10-2021
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)22-10-2021
Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for Board Meeting Intimation
Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2021 ,inter alia, to consider and approve NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited ('the Company') is scheduled to be held on Friday, 29th October, 2021 to, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and half year ended 30th September, 2021.22-10-2021
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING21-10-2021
Eris Lifesciences Ltd - 540596 - Shareholding for the Period Ended September 30, 2021
Eris Lifesciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here18-10-2021
Eris Lifesciences Ltd - 540596 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- MILIND TALEGAONKARDesignation :- Company Secretary and Compliance Officer11-10-2021